ArticleThe Journal of antimicrobial chemotherapy2022
Liposomal amphotericin B-the past.
Article in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations.The Journal of antimicrobial chemotherapy · 2026Review
- Bronchoscopic local instillation of amphotericin B deoxycholate as adjunctive therapy for pulmonary mucormycosis with inadequate response to posaconazole: a retrospective case series.Frontiers in medicine · 2026Article
- In Vitro Assessment of the Combined Activity of Amphotericin B and CuTropical medicine and infectious disease · 2025Article
- Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistantAntimicrobial agents and chemotherapy · 2025Observational
- Advancing antifungal therapy: exploring targeted CFW-PEc-enhanced ethosomal formulations of amphotericin B against cryptococcal pneumonia.Microbiology spectrum · 2025Article
- Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective.Journal of clinical medicine · 2025Review
- Clinical impact of fluconazole-resistantFuture microbiology · 2025Review
- Article
- Antifungal drug resistance in Candida glabrata: role of cellular signaling and gene regulatory networks.FEMS yeast research · 2025Review
- Efficacy and Safety of Amphotericin B Colloidal Dispersion via Nebulized Inhalation Combined with Intravenous Therapy for Invasive Pulmonary Fungal Disease: A Single-Center, Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.PLoS neglected tropical diseases · 2025Review
- Innovative antifungal strategies to combat drug-resistantFrontiers in cellular and infection microbiology · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Sphaeropsidin A Loaded in Liposomes to Reduce Its Cytotoxicity and Preserve Antifungal Activity AgainstMolecules (Basel, Switzerland) · 2024Article
- Diverse antifungal potency of terbinafine as a therapeutic agent against Exophiala dermatitidis in vitro.Scientific reports · 2024Article
- Paving the way for affordable and equitable liposomal amphotericin B access worldwide.The Lancet. Global health · 2024Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis.BMC infectious diseases · 2024Article
- Diagnosis and treatment of peritoneal dialysis associated mycotic peritonitis caused byMedical mycology case reports · 2024Article
- Antarctic fungi produce pigment with antimicrobial and antiparasitic activities.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
The discovery of amphotericin B, a polyene antifungal compound, in the 1950s, and the formulation of this compound in a liposomal drug delivery system, has resulted in decades of use in systemic fungal infections. The use of liposomal amphotericin B formulation is referenced in many international guidelines for the treatment of fungal infections such as Aspergillus and cryptococcal disease and Candida infections, as well as other less common infections such as visceral leishmaniasis. With the development of liposomal amphotericin B, an improved therapeutic index could be achieved that allowed the attainment of higher drug concentrations in both the plasma and tissue while simultaneously lowering the toxicity compared with amphotericin B deoxycholate. In over 30 years of experience with this drug, a vast amount of information has been collected on preclinical and clinical efficacy against a wide variety of pathogens, as well as evidence on its toxicity. This article explores the history and nature of the liposomal formulation, the key clinical studies that developed the pharmacokinetic, safety and efficacy profile of the liposomal formulation, and the available microbiological data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.